Medicure Inc.

Medicure Inc. (TSX-V: MPH) (OTC: MCUJF) is a specialty pharmaceutical company headquartered in Winnipeg, Manitoba, Canada, focused on the development and commercialization of cardiovascular pharmaceutical products in the United States and Canadian markets. According to its website at medicure.com, the company markets AGGRASTAT (tirofiban hydrochloride) — an intravenous antiplatelet agent used in the treatment of acute coronary syndrome — through its U.S. commercial operations, providing hospitals and cardiac catheterization laboratories with a specialized cardiovascular pharmaceutical product used during coronary interventions to prevent blood clots in patients undergoing angioplasty and coronary stenting procedures. Medicure's commercial focus on a specialized hospital-based cardiovascular pharmaceutical reflects its strategy of operating in the high-value niche cardiovascular market where clinical expertise and hospital customer relationships drive product adoption.

Medicure's commercial pharmaceutical operations, described at medicure.com, center on maintaining and growing the market position of AGGRASTAT in U.S. and Canadian hospital markets through direct sales engagement with interventional cardiologists, catheterization laboratory directors, and pharmacy buyers who influence the selection of antiplatelet therapy for acute coronary syndrome patients. The company's U.S. commercial team works within hospital formulary and procurement processes to position AGGRASTAT as a preferred antiplatelet option in institutions managing significant volumes of cardiac catheterization and percutaneous coronary intervention procedures. Medicure's hospital-focused commercial model requires deep knowledge of hospital purchasing processes, formulary decision-making, and clinical pharmacy and cardiology practice that the company has developed through its years of operating in the cardiovascular hospital pharmaceutical market.

Medicure also pursues development activities aimed at expanding its cardiovascular pharmaceutical portfolio beyond AGGRASTAT through development of new formulations, new indications, or new cardiovascular drug candidates that can leverage the company's cardiovascular market expertise and hospital commercial infrastructure. According to medicure.com, the company's combination of established commercial operations generating revenue from AGGRASTAT and ongoing development activities creates a balanced pharmaceutical business model that seeks to sustain and grow the core AGGRASTAT business while investing in the development of additional cardiovascular products that can extend Medicure's commercial franchise over the long term. Medicure's combination of marketed cardiovascular pharmaceutical product, specialized hospital market commercial operations, cardiovascular clinical expertise, and dual TSX-V and OTC listing provides investors with exposure to a specialty cardiovascular pharmaceutical company with an established commercial product in the acute cardiac care market.